Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Divestments (2021 - 2025)

BridgeBio Pharma's Divestments history spans 3 years, with the latest figure at $2.3 million for Q3 2025.

  • For Q3 2025, Divestments changed N/A year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, down 91.04%, while the annual FY2025 figure was $2.3 million, 91.04% down from the prior year.
  • Divestments for Q3 2025 was $2.3 million at BridgeBio Pharma, down from $25.7 million in the prior quarter.
  • Across five years, Divestments topped out at $29.4 million in Q4 2021 and bottomed at $2.3 million in Q3 2025.
  • The 3-year median for Divestments is $25.7 million (2024), against an average of $19.1 million.